Separate Safety Center Could Impair Oversight “Continuity” - Von Eschenbach
Executive Summary
Creating "separate and independent" centers for drug approval and post-approval safety surveillance "would not improve the FDA's ability to fulfill its mission to protect the public health," FDA Acting Commissioner Andrew von Eschenbach asserted
You may also be interested in...
Von Eschenbach’s Commissioner Debut May Be Release Of Safety Report
One of Andrew von Eschenbach's first major steps as FDA commissioner is likely to be release of the agency task force response to the Institute of Medicine's recommendations to improve drug safety oversight
Von Eschenbach’s Commissioner Debut May Be Release Of Safety Report
One of Andrew von Eschenbach's first major steps as FDA commissioner is likely to be release of the agency task force response to the Institute of Medicine's recommendations to improve drug safety oversight
FDA Drug Safety Reforms Not Enough To Fix Problems, IoM Committee Says
A separate postmarketing safety center may become necessary if the recommendations made by the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System do not result in sufficient reforms of FDA's safety oversight, the committee says